NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

TRAMADOL/ACETAMINOPHEN TABLETS (ULTRACET(r)) VERSUS HYDROCODONE BITARTRATE/ACETAMINOPHEN FOR DENTAL PAIN.

Jordan DM, Fricke JR, Jordan DM, Hewitt DJ, Rosenthal N, Karim MR; AcademyHealth. Meeting (2005 : Boston, Mass.).

Abstr AcademyHealth Meet. 2005; 22: abstract no. 4119.

CNS Projects, Ortho-McNeil Pharmaceutical, 1000 Route 202, Raritan, NJ 08869-0602 Tel. (908) 704-5833 Fax (908) 218-7051

RESEARCH OBJECTIVE: To compare the efficacy and safety of tramadol 37.5 mg/acetaminophen (APAP) 325 mg tablets and hydrocodone bitartrate10 mg/APAP 650 mg tablets for dental pain. STUDY DESIGN: Randomized, doubled-blind, placebo- and active-controlled, single-dose, parallel study. Subjects received 1 or 2 tramadol/APAP tablets, 1 hydrocodone/APAP tablet, or placebo. Pain intensity and relief were reported 30 minutes and then hourly for 8 hours, and time to onset of perceptible pain relief was recorded. Summary scores of pain relief and intensity over 4 hours and 8 hours were primary outcomes. POPULATION STUDIED: Two hundred adults experiencing at least moderate pain (Pain Visual Analog Score >=50/100 mm) following extraction of >=2 impacted third molars. PRINCIPAL FINDINGS: Baseline characteristics were similar among groups. One tramadol/APAP tablet was more effective than placebo for select outcomes over 4 hours; two tramadol/APAP tablets and one hydrocodone/APAP tablet were more effective than placebo for up to 8 hours. Among treatment groups, two tramadol/APAP tablets were more effective than one tramadol/APAP tablet over 4 hours: total pain relief (TOTPAR, P = .031), sum of pain intensity differences (SPID, P = .017), and sum of pain relief and intensity differences (SPRID, P = .023). Two tramadol/APAP tablets were comparable to hydrocodone/APAP throughout: TOTPAR (P >= .082), SPID (P >=.144), and SPRID (P >= .095). All treatments had faster onset than placebo; median onset of perceptible pain relief for two tramadol/APAP tablets was 33.3 minutes. The overall incidence of adverse events was lower for tramadol/APAP tablets than for hydrocodone/APAP or placebo, and the incidence of nausea and vomiting with two tramadol/APAP tablets was approximately 50% less than in the hydrocodone/APAP group. CONCLUSIONS: Tramadol/APAP tablets provide rapid, dose-dependent pain relief. The use of two tramadol/APAP tablets is an effective and safe alternative to hydrocodone/APAP for dental pain. IMPLICATIONS FOR POLICY, DELIVERY OR PRACTICE: Tramadol/APAP should be considered as an alternative to high-dose hydrocodone/APAP in the treatment of acute pain on account of its efficacy and favorable tolerability profile.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acetaminophen
  • Adult
  • Analgesia
  • Double-Blind Method
  • Drug Combinations
  • Humans
  • Hydrocodone
  • Molar, Third
  • Nausea
  • Pain
  • Pain Measurement
  • Placebos
  • Toothache
  • Tramadol
  • Ultracet
  • hsrmtgs
UI: 103623582

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov